155 related articles for article (PubMed ID: 34247888)
21. Inverse Relation between MxA Gene Expression and Age in Multiple Sclerosis Patients Reveals a Gender Difference in Response to Interferon Therapy.
Taheri M; Mirinezhad M; Omrani MD; Sajjadi E; Inoko H; Sayad A
Iran J Allergy Asthma Immunol; 2017 Feb; 16(1):21-27. PubMed ID: 28417621
[TBL] [Abstract][Full Text] [Related]
22. Disability progression
von Wyl V; Benkert P; Moser A; Lorscheider J; Décard B; Hänni P; Lienert C; Kuhle J; Derfuss T; Kappos L; Yaldizli Ö
Mult Scler; 2021 Mar; 27(3):439-448. PubMed ID: 32463336
[TBL] [Abstract][Full Text] [Related]
23. Cytotoxic B Cells in Relapsing-Remitting Multiple Sclerosis Patients.
Boldrini VO; Marques AM; Quintiliano RPS; Moraes AS; Stella CRAV; Longhini ALF; Santos I; Andrade M; Ferrari B; Damasceno A; Carneiro RPD; Brandão CO; Farias AS; Santos LMB
Front Immunol; 2022; 13():750660. PubMed ID: 35197967
[TBL] [Abstract][Full Text] [Related]
24. Correlation between IL-31 and sCD40L plasma levels in Fingolimod-treated patients with Relapsing-Remitting Multiple Sclerosis (RRMS).
Gonçalves MVM; Brandão WN; Longo C; Peron JPS; Dos Passos GR; Pagliarini GL; do Nascimento OJM; Marinowic DR; Machado DC; Becker J
J Neuroimmunol; 2020 Nov; 350():577435. PubMed ID: 33189062
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Expression Levels of miR-29b-3p and miR-326 in T Helper-1 and T Helper-17 Cells Isolated from Responsive and Non-responsive Relapsing-remitting Multiple Sclerosis Patients Treated with Interferon-beta.
Karimi L; Eskandari N; Shaygannejad V; Zare N; Andalib A; Khanahmad H; Mirmosayyeb O
Iran J Allergy Asthma Immunol; 2020 Aug; 19(4):416-425. PubMed ID: 33463108
[TBL] [Abstract][Full Text] [Related]
26. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis.
Trenova AG; Slavov GS; Manova MG; Kostadinova II
Arch Med Res; 2014 Aug; 45(6):495-500. PubMed ID: 25130430
[TBL] [Abstract][Full Text] [Related]
27. Interleukins (IL-23 and IL-27) serum levels: Relationships with gene polymorphisms and disease patterns in multiple sclerosis patients under treatment with interferon and glatiramer acetate.
Barac IS; Văcăraș V; Iancu M; Mureșanu DF; Procopciuc LM
Heliyon; 2023 Jun; 9(6):e17427. PubMed ID: 37484355
[TBL] [Abstract][Full Text] [Related]
28. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
29. Multiple sclerosis and immune system biomarkers: Novel comparison in glatiramer acetate and interferon beta-1a-treated patient groups.
Pavelek Z; Novotny M; Soucek O; Krejsek J; Sobisek L; Sejkorova I; Masopust J; Kuca K; Valis M; Klimova B; Stourac P
Mult Scler Relat Disord; 2021 Aug; 53():103082. PubMed ID: 34166982
[TBL] [Abstract][Full Text] [Related]
30. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.
González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA
J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665
[TBL] [Abstract][Full Text] [Related]
31. The alterations of cerebrospinal fluid TNF-alpha and TGF-beta2 levels in early relapsing-remitting multiple sclerosis.
Grzegorski T; Iwanowski P; Kozubski W; Losy J
Immunol Res; 2022 Oct; 70(5):708-713. PubMed ID: 35729473
[TBL] [Abstract][Full Text] [Related]
32. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.
Simpson D; Noble S; Perry C
CNS Drugs; 2002; 16(12):825-50. PubMed ID: 12421116
[TBL] [Abstract][Full Text] [Related]
33. Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis.
Simpson D; Noble S; Perry C
BioDrugs; 2003; 17(3):207-10. PubMed ID: 12749757
[TBL] [Abstract][Full Text] [Related]
34. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
Soini E; Joutseno J; Sumelahti ML
Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
[TBL] [Abstract][Full Text] [Related]
35. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
Li H; Hu F; Zhang Y; Li K
J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710
[TBL] [Abstract][Full Text] [Related]
36. Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
Río J; Rovira A; Tintoré M; Sastre-Garriga J; Castilló J; Auger C; Nos C; Comabella M; Tur C; Vidal Á; Montalbán X
Mult Scler; 2014 Oct; 20(12):1602-8. PubMed ID: 24622350
[TBL] [Abstract][Full Text] [Related]
37. Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis.
Trenova AG; Manova MG; Kostadinova II; Murdjeva MA; Hristova DR; Vasileva TV; Zahariev ZI
Folia Med (Plovdiv); 2011; 53(2):29-35. PubMed ID: 21797104
[TBL] [Abstract][Full Text] [Related]
38. The Effect of IFN-β Treatment on Plasma Levels of BDNF and IL-6 in Relapsing-Remitting Multiple Sclerosis Patients.
Shajarian M; Alsahebfosoul F; Etemadifar M
Neuroimmunomodulation; 2021; 28(3):150-157. PubMed ID: 34182566
[TBL] [Abstract][Full Text] [Related]
39. Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study.
Meca-Lallana JE; Balseiro JJ; Lacruz F; Guijarro C; Sanchez O; Cano A; Costa-Frossard L; Hernández-Clares R; Sanchez-de la Rosa R;
J Neurol Sci; 2012 Apr; 315(1-2):123-8. PubMed ID: 22133480
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study.
Darbà J; Kaskens L; Sánchez-de la Rosa R
J Med Econ; 2014 Mar; 17(3):215-22. PubMed ID: 24494728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
